Yoles I. et al. Efficacy and Safety of Standard vs Low dose of Femarelle for the treatment of Menop. Symptoms

"...significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of treatment."

Lue Lisää

Labos g., Trakakis E. et al. Efficacy and Safety of DT56a (Femarelle) compared to hormone therapy

"DT56a decreased menopausal symptoms significantly and in the same degree as HT."

Lue Lisää

Genazzani AR et al. Brain region responsivness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats

""

Lue Lisää

Nachtigall M. et al. A Prospective Study of DT56a (Femarelle) for the Treatment of Postmenopausal Vaginal atrophy

""

Lue Lisää

Yoles I. et al. Femarelle - a New Phyto-Selective Estrogen Receptor Modulator-like substance for the Treatment of Postmenopausal Bone loss

""

Lue Lisää

Somjen D, Yoles I. DT56a (Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus

""

Lue Lisää

Somjen D., et al. DT56a (Femarelle) Stimulates Bone formation in Female Rats

""

Lue Lisää

Somjen D., et al. DT56a (Femarelle) Stimulates Gender-Specific Human Cultures Bone cells

""

Lue Lisää

Somjen D. et al. The Effects of Native and Synthetic Estrogenic Compounds as w. as Vit D Less-Calcemic Analogs on Adipocytes Cont. in Rat Bone Marrow

""

Lue Lisää